Trial Profile
Immunotherapy for Unresectable Pancreas Cancer: A Phase 1 Study of Intratumoral Recombinant Fowlpox PANVAC (PANVAC-F) Plus Subcutaneous Recombinant Vaccinia PANVAC (PANVAC-V), PANVAC-F and Recombinant Granulocyte-Macrophage Colony Stimulating Factor (rH-GM-CSF)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs CV 301 (Primary) ; Falimarev; Falimarev; Inalimarev; Sargramostim
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 27 Apr 2023 Planned End Date changed from 14 Apr 2023 to 14 Apr 2024.
- 15 Apr 2022 Planned End Date changed from 1 Apr 2022 to 14 Apr 2023.
- 04 Jan 2022 Planned End Date changed from 15 Dec 2021 to 1 Apr 2022.